文献速递临床血液与体液分子诊断临床免疫

血液系统肿瘤可测量残留病:当前检测格局与未来方向

The essentials-measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions.
PubMed 文献 · Am J Clin Pathol · 2026-01-01

本文综述了急性白血病、多发性骨髓瘤和慢性淋巴细胞白血病中可测量残留病(MRD)的监测方法,讨论了应用流式细胞术和分子技术评估MRD的路径。文章指出合理使用辅助技术、结合临床背景解读结果并将结果纳入疾病管理对改善结局至关重要,同时强调共识指南持续更新及新兴技术和实验室可及性是病理学家实施MRD分析的重要考量。

要点

  • MRD状态在无形态学疾病时具有预后价值,可直接影响治疗决策。
  • 合理使用流式细胞术和分子技术是评估MRD的关键。
  • MRD结果需结合临床背景解读并纳入疾病管理以改善结局。

核心结论

  • MRD分析已成为多种血液系统肿瘤常规临床管理的重要组成部分。
  • 合理应用辅助技术、结合临床背景解读并将结果纳入疾病管理对改善结局至关重要。
  • MRD评估的共识指南持续更新,新兴技术和实验室可及性是实施MRD分析的重要实际考量。

研究设计与样本

  • 综述,描述了急性白血病、多发性骨髓瘤和慢性淋巴细胞白血病中的MRD监测方法。

主要发现

  • 无形态学疾病时的MRD状态具有预后价值,可急性影响治疗决策。
  • 使用流式细胞术和分子技术评估这些血液系统肿瘤的MRD。
  • 解读MRD结果具有挑战性且常需要专业知识。

临床怎么用

  • 病理学家可从中获得应用和解读先进研究以评估血液系统恶性肿瘤患者MRD状态的经验性视角。
  • 将MRD结果纳入疾病管理对改善结局至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Measurable residual disease (MRD) analysis, also known as minimal residual disease analysis, has become an essential component of routine clinical management in many hematopoietic neoplasms. Measurable residual disease status in the absence of morphologic disease holds prognostic value and can acutely affect treatment decisions. METHODS: Measurable residual disease monitoring is described in acute leukemia, multiple myeloma, and chronic lymphocytic leukemia. We discuss the approach to MRD assessment of these hematologic neoplasms using flow cytometry and molecular techniques. RESULTS: The appropriate use of available ancillary techniques is crucial to assess patients for MRD. Interpreting these results in the appropriate clinical context is challenging and often requires expertise. Incorporating the results into disease management is critical for improved outcomes. CONCLUSIONS: Consensus guidelines on MRD assessment in hematopoietic neoplasms continue to evolve. Further, emerging technologies and laboratory availability are important practical considerations for pathologists who are implementing MRD analysis. From this review, pathologists can gain an anecdotal perspective on the application and interpretation of advanced studies to assess the MRD status of patients with hematopoietic malignancies.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Gisriel SD, Siddon A. The essentials-measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions. Am J Clin Pathol. 2026. PMID: 42424499. doi:10.1093/ajcp/aqag079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。